AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$MRNA

Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat

Moderna's shares fell 25.2% to $183.88, losing $24B in market value, after late-stage trial data for its melanoma vaccine showed a 42% reduction in cancer recurrence or death. Analysts attributed the drop to a 'sell-the-news' reaction. Merck, its partner, saw a 1% decline. Both companies plan to discuss results further at an oncology meeting.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 7:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MRNABearishMed
01

Why it matters

The data release triggered a classic sell‑the‑news reaction, wiping out $24 billion from Moderna's market cap and causing a 25% one‑day plunge, with Merck also slipping.

02

Market read

First‑time disclosure of pivotal trial data caused a sharp, immediate price decline, presenting short‑term trading opportunities.

03

What to watch

Long‑term efficacy and future indications for the vaccine could still support a higher valuation despite the sell‑off.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Moderna and Merck announced late‑stage trial results for a personalized melanoma vaccine (intismeran) that showed a 42% reduction in recurrence risk versus Keytruda alone.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna's shares fell 25% after its late‑stage melanoma vaccine trial data were released, wiping out about $24 billion in market value.

Expected impact

likely continued downward pressure as the market prices in the trial data and the sharp price drop.

Evidence & confidence

The trial results were the first public disclosure and triggered a 25% one‑day decline; traders may still be adjusting positions.

$MRKBearishMedium confidence
Context

Merck's shares slipped nearly 1% following the same melanoma vaccine data release that drove Moderna's plunge.

Expected impact

likely modest further pressure as investors assess Merck's exposure to the vaccine partnership.

Evidence & confidence

Merck's move is secondary to Moderna's but still reflects market reaction to the trial outcome.

Market effects

Sector

Biotech and oncology sectors may see heightened volatility as investors reassess valuation multiples after a large sell‑the‑news move.

Regional

U.S. biotech stocks could face broader pressure in the afternoon session.

Global

Limited to biotech investors; no immediate macro impact.

Counterpoint

What could challenge this read

Some traders may view the sharp drop as an over‑reaction and look for a short‑term rebound if the data hold up.

Key entities

  • Company
    Moderna

    Biotech firm developing the melanoma vaccine.

  • Company
    Merck

    Partner providing Keytruda immunotherapy.

Read at source← All news

StoryMerck and Moderna report positive Phase 3 melanoma vaccine results

Also covered by

6 outlets

Related articles

OCT 22
$MRNAHighAI 8/10

Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.

Moderna's stock fell 25% on Thursday despite positive leaked data showing its cancer vaccine, developed with Merck, reduced melanoma recurrence risk by over 40% when combined with Keytruda. The vaccine also reduced cancer spread risk by 38%. Moderna's stock has risen over 500% this year on vaccine expectations. The trial focused on personalized treatment for melanoma, with experts calling it a landmark in cancer research.

finance.yahoo.com2 min
OCT 22
$MRKMed

Merck (MRK) Reports Promising Phase 3 Trial Results for mRNA The

Merck (MRK) reported positive Phase 3 trial results for its mRNA-based therapy intismeran autogene combined with KEYTRUDA, showing reduced risk of recurrence or death in melanoma patients. The company has a 2.41% dividend yield but a high payout ratio of 1.11, raising sustainability concerns. MRK's GF Score is 79/100, with strong profitability but weak momentum. Insiders have sold $71.4M in shares, and gurus are trimming positions. The stock is trading 22.5% above its GF Value of $121.00.

gurufocus.com3 min
OCT 22
$MRKHigh

Merck (MRK) Gains Favor as INTerpath-001 Trial Shows Promising M

Merck (MRK) gains investor attention after Phase 3 INTerpath-001 trial shows promising recurrence-free survival data for intismeran autogene in melanoma treatment. Wells Fargo maintains an Overweight rating with a $165 price target. Merck's dividend yield is 2.41%, but its payout ratio is high at 111%, raising sustainability concerns. The stock trades 22.5% above its intrinsic value of $121, indicating modest overvaluation.

gurufocus.com3 min